标题
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
作者
关键词
-
出版物
Advanced Science
Volume 8, Issue 22, Pages 2101672
出版商
Wiley
发表日期
2021-10-21
DOI
10.1002/advs.202101672
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion
- (2021) Nicole E. Scharping et al. NATURE IMMUNOLOGY
- IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
- (2021) Yuying Liu et al. NATURE IMMUNOLOGY
- CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability
- (2021) Xingzhe Ma et al. Cell Metabolism
- Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
- (2021) James J. Harding et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates in solid tumors: a look into novel targets
- (2021) Carmen Criscitiello et al. Journal of Hematology & Oncology
- Targeting a neoantigen derived from a common TP53 mutation
- (2021) Emily Han-Chung Hsiue et al. SCIENCE
- TCR β chain–directed bispecific antibodies for the treatment of T cell cancers
- (2021) Suman Paul et al. Science Translational Medicine
- Photocatalysis-mediated drug-free sustainable cancer therapy using nanocatalyst
- (2021) Bin Zhao et al. Nature Communications
- Bispecific antibodies targeting mutant RAS neoantigens
- (2021) Jacqueline Douglass et al. Science Immunology
- Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer
- (2021) Ran Li et al. Nature Nanotechnology
- Designation Products: Boron Neutron Capture Therapy for Head and Neck Carcinoma
- (2021) Hitoshi Kanno et al. ONCOLOGIST
- Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
- (2020) John Timmerman et al. AMERICAN JOURNAL OF HEMATOLOGY
- Regulatory T Cells and Human Disease
- (2020) Shimon Sakaguchi et al. Annual Review of Immunology
- VISTA: Coming of age as a multi‐lineage immune checkpoint
- (2020) M. A. ElTanbouly et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Peripheral T cell expansion predicts tumour infiltration and clinical response
- (2020) Thomas D. Wu et al. NATURE
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy
- (2020) David G. Millar et al. NATURE BIOTECHNOLOGY
- The therapeutic landscape for cells engineered with chimeric antigen receptors
- (2020) Matthew MacKay et al. NATURE BIOTECHNOLOGY
- CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
- (2020) Haiping Wang et al. NATURE IMMUNOLOGY
- The entry of nanoparticles into solid tumours
- (2020) Shrey Sindhwani et al. NATURE MATERIALS
- Neutrophils as emerging therapeutic targets
- (2020) Tamás Németh et al. NATURE REVIEWS DRUG DISCOVERY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
- (2020) Mohamed A. ElTanbouly et al. SCIENCE
- A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
- (2020) Dimitris Skokos et al. Science Translational Medicine
- Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
- (2020) Hyunbo Shim Biomolecules
- Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity
- (2020) Yiwen Lu et al. CELL
- Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
- (2020) Florian Klemm et al. CELL
- Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
- (2020) Jean-Christophe Beltra et al. IMMUNITY
- A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).
- (2020) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
- (2020) Thorsten Oliver Goetze et al. JOURNAL OF CLINICAL ONCOLOGY
- Targets and Antibody Formats for Immunotherapy of Neuroblastoma
- (2020) Jeong A. Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
- (2020) Jing Huang et al. LANCET ONCOLOGY
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer
- (2020) Hae-Ock Lee et al. NATURE GENETICS
- CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
- (2020) Miguel Gaspar et al. Cancer Immunology Research
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Immunogenomic Landscape of Hematological Malignancies
- (2020) Olli Dufva et al. CANCER CELL
- Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma
- (2020) Christian Bailly CHEMICO-BIOLOGICAL INTERACTIONS
- The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
- (2020) Tobias Bald et al. NATURE IMMUNOLOGY
- Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen
- (2020) Santosha A. Vardhana et al. NATURE IMMUNOLOGY
- Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity
- (2020) Chang Liu et al. NATURE IMMUNOLOGY
- Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
- (2020) Lukas F. Mager et al. SCIENCE
- Opportunities for Small Molecules in Cancer Immunotherapy
- (2020) Sabina Y. van der Zanden et al. TRENDS IN IMMUNOLOGY
- Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy
- (2020) Shuren Wang et al. Advanced Healthcare Materials
- Photogenerated holes induced rapid eliminating of solid tumors by the supramolecular porphyrin photocatalyst
- (2020) Zijian Zhang et al. National Science Review
- What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
- (2020) Duxin Sun et al. ACS Nano
- 1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
- (2020) N. Lakhani et al. ANNALS OF ONCOLOGY
- 525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
- (2020) G. Ku et al. ANNALS OF ONCOLOGY
- Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies
- (2020) Jingwen Si et al. CANCER CELL
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- (2020) Catherine S. Grasso et al. CANCER CELL
- Advances in chimeric antigen receptor T cells
- (2020) Ofrat Beyar-Katz et al. CURRENT OPINION IN HEMATOLOGY
- T cell immunity to hepatitis C virus: lessons for a prophylactic HCV vaccine
- (2020) Robert Thimme JOURNAL OF HEPATOLOGY
- Targeted glycan degradation potentiates the anticancer immune response in vivo
- (2020) Melissa A. Gray et al. Nature Chemical Biology
- Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion
- (2020) Yi-Ru Yu et al. NATURE IMMUNOLOGY
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical landscape of oncolytic virus research in 2020
- (2020) Nicholas Macedo et al. Journal for ImmunoTherapy of Cancer
- New emerging targets in cancer immunotherapy: the role of GITR
- (2020) Giulia Buzzatti et al. ESMO Open
- Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials
- (2020) Seyed Samad Hosseini et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Mechanism of EBV inducing anti-tumour immunity and its therapeutic use
- (2020) Il-Kyu Choi et al. NATURE
- Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade
- (2020) Yang Liu et al. Cell Death & Disease
- Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B
- (2020) Greta Acerbi et al. JOURNAL OF HEPATOLOGY
- Photoredox catalysis using infrared light via triplet fusion upconversion
- (2019) Benjamin D. Ravetz et al. NATURE
- Delivery technologies for cancer immunotherapy
- (2019) Rachel S. Riley et al. NATURE REVIEWS DRUG DISCOVERY
- Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
- (2019) Juan J. Miret et al. Journal for ImmunoTherapy of Cancer
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
- (2019) Jun Wang et al. NATURE MEDICINE
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Landscape of B cell immunity and related immune evasion in human cancers
- (2019) Xihao Hu et al. NATURE GENETICS
- Specific Decrease in B-Cell-Derived Extracellular Vesicles Enhances Post-Chemotherapeutic CD8+ T Cell Responses
- (2019) Fanghui Zhang et al. IMMUNITY
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
- (2019) Laura M. McLane et al. Annual Review of Immunology
- Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
- (2019) Mikhail Binnewies et al. CELL
- Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
- (2019) Xingzhe Ma et al. Cell Metabolism
- Phase II study of a telomerase-specific oncolytic adenovirus (OBP-301, Telomelysin) in combination with pembrolizumab in gastric and gastroesophageal junction adenocarcinoma.
- (2019) Uqba Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
- (2019) Timothy A Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I open label study evaluating VT1021 in patients with advanced solid tumors.
- (2019) Michael Cieslewicz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
- (2019) Nataliya Volodymyrivna Uboha et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
- (2019) Jing Nie et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
- (2019) Mauro Di Pilato et al. NATURE
- Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
- (2019) Deepali V. Sawant et al. NATURE IMMUNOLOGY
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
- (2019) Linda Hammerich et al. NATURE MEDICINE
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ
- (2019) Chang Liu et al. IMMUNITY
- Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses
- (2019) Amare Aregay et al. JOURNAL OF HEPATOLOGY
- TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
- (2019) Francesca Alfei et al. NATURE
- TOX is a critical regulator of tumour-specific T cell differentiation
- (2019) Andrew C. Scott et al. NATURE
- CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
- (2019) Amira A. Barkal et al. NATURE
- TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
- (2019) Omar Khan et al. NATURE
- Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection
- (2019) Chen Yao et al. NATURE IMMUNOLOGY
- Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
- (2019) Shinichi Yachida et al. NATURE MEDICINE
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Optimizing oncolytic virotherapy in cancer treatment
- (2019) Kevin Harrington et al. NATURE REVIEWS DRUG DISCOVERY
- Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
- (2019) Matthew B. Dong et al. CELL
- PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
- (2019) Martin W. LaFleur et al. NATURE IMMUNOLOGY
- Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity
- (2019) Paramita Chakraborty et al. Cell Reports
- The Global Landscape of EBV-Associated Tumors
- (2019) Claire Shannon-Lowe et al. Frontiers in Oncology
- 1202PPhase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
- (2019) N Mach et al. ANNALS OF ONCOLOGY
- 1209PExcellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1
- (2019) V Radhakrishnan et al. ANNALS OF ONCOLOGY
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1
- (2019) Amer M Zeidan et al. BLOOD
- Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies
- (2019) Philippe Armand et al. BLOOD
- B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
- (2019) Daniel P. Hollern et al. CELL
- Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
- (2019) Qiming Zhang et al. CELL
- EP1.04-23 Ongoing Phase II Trial of Anti-PD1 Therapy in Combination with CIMAvax-EGF in Patients with Advanced NSCLC or Squamous Cell Head and Neck Cancer
- (2019) G. Dy et al. Journal of Thoracic Oncology
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- MHC-II neoantigens shape tumour immunity and response to immunotherapy
- (2019) Elise Alspach et al. NATURE
- VISTA is an acidic pH-selective ligand for PSGL-1
- (2019) Robert J. Johnston et al. NATURE
- Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
- (2019) Oliver Kepp et al. Nature Reviews Clinical Oncology
- Sphingosine 1-phosphate: Lipid signaling in pathology and therapy
- (2019) Andreane Cartier et al. SCIENCE
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
- (2019) Caroline S. Jansen et al. NATURE
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
- (2019) Sangeeta Goswami et al. NATURE MEDICINE
- Immune agonist antibodies face critical test
- (2019) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- Engineering nanoparticle strategies for effective cancer immunotherapy
- (2018) Hong Yeol Yoon et al. BIOMATERIALS
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8 + T Cells
- (2018) Jing Li et al. IMMUNITY
- Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells
- (2018) Bertram Bengsch et al. IMMUNITY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- The market for chimeric antigen receptor T cell therapies
- (2018) Amy Yip et al. NATURE REVIEWS DRUG DISCOVERY
- Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
- (2018) Chi Ma et al. SCIENCE
- Personalized vaccines for cancer immunotherapy
- (2018) Ugur Sahin et al. SCIENCE
- A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
- (2018) Devalingam Mahalingam et al. Cancers
- Evolutionary Pressure against MHC Class II Binding Cancer Mutations
- (2018) Rachel Marty et al. CELL
- A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
- (2018) Sadhna Shankar et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
- (2018) Sarina Anne Piha-Paul et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
- (2018) Fabrice Barlesi et al. LANCET ONCOLOGY
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
- (2018) Ben Tran et al. Journal for ImmunoTherapy of Cancer
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
- (2018) Nadine van Montfoort et al. CELL
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
- (2018) Hanjie Li et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy
- (2018) Lingyun Li et al. Cell Metabolism
- CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity
- (2018) Laura M. Snell et al. IMMUNITY
- Engineering therapeutic bispecific antibodies using CrossMab technology
- (2018) Christian Klein et al. METHODS
- Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
- (2018) Lei Zhang et al. NATURE
- An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma
- (2018) Bo Xu et al. NATURE BIOTECHNOLOGY
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- p95HER2–T cell bispecific antibody for breast cancer treatment
- (2018) Irene Rius Ruiz et al. Science Translational Medicine
- Transcription Factor IRF4 Promotes CD8 + T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection
- (2017) Kevin Man et al. IMMUNITY
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
- (2017) Jennifer L. Guerriero et al. NATURE
- Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B
- (2017) Paola Fisicaro et al. NATURE MEDICINE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma.
- (2017) D. Shafren et al. JOURNAL OF CLINICAL ONCOLOGY
- Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer
- (2016) Sunil Singhal et al. CANCER CELL
- Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
- (2016) Laura Q.M. Chow et al. CLINICAL CANCER RESEARCH
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
- (2016) Roberto Tinoco et al. IMMUNITY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- MP13-19 A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
- (2016) Vignesh T. Packiam et al. JOURNAL OF UROLOGY
- Targeting metastasis-initiating cells through the fatty acid receptor CD36
- (2016) Gloria Pascual et al. NATURE
- Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
- (2016) B Benzon et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- Carcinogenic human papillomavirus infection
- (2016) Mark Schiffman et al. Nature Reviews Disease Primers
- The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
- (2015) Jacques F.A.P. Miller et al. CANCER CELL
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial
- (2015) Naomi B Haas et al. Journal for ImmunoTherapy of Cancer
- Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer
- (2014) Evgeniy B. Eruslanov et al. JOURNAL OF CLINICAL INVESTIGATION
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Structure-based programming of lymph-node targeting in molecular vaccines
- (2014) Haipeng Liu et al. NATURE
- Neutrophils scan for activated platelets to initiate inflammation
- (2014) Vinatha Sreeramkumar et al. SCIENCE
- Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma
- (2013) Matija Snuderl et al. CELL
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis
- (2013) Greg M. Delgoffe et al. NATURE
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling
- (2011) Mathieu Bergé et al. JOURNAL OF HEPATOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
- (2009) Zvi G. Fridlender et al. CANCER CELL
- Neuropilin-1: The Glue between Regulatory T Cells and Dendritic Cells?
- (2008) Masayuki Mizui et al. IMMUNITY
- Multiple roles for CD4+T cells in anti-tumor immune responses
- (2008) Richard Kennedy et al. IMMUNOLOGICAL REVIEWS
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- (2008) Alessandro Testori et al. JOURNAL OF CLINICAL ONCOLOGY
- An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
- (2008) Christopher Wood et al. LANCET
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now